CompanyGraph
Sells spinal implants and a surgical robot that legally lock surgeons into using them together.
- Depends onDownstream position: depends on 8 industries, supplies 3
- ScaleMarket cap is above the global median
- FinancialsAltman Z-Score: safe zone
- Interpretations5 currently firing — 1 · 4
What this company is and how it runs — written from structure, not news.
Globus Medical sells titanium and cobalt-chromium spinal implants paired with its Excelsius surgical robot, but each implant-robot combination requires its own FDA 510(k) clearance before surgeons can legally use it in the operating room. Those clearances depend on clinical data generated through hands-on cadaveric training at Globus's Audubon facility, so the physical laboratory — its floor space and its cadaver supply — is the actual bottleneck controlling how fast new procedure types can be approved and sold. Because a surgeon's Excelsius certification does not transfer to any competing robot, and because hospitals have wired the robot's navigation software into their own imaging systems, switching would mean retraining staff from scratch under a different clearance framework entirely. The whole structure depends on Audubon continuing to operate: if cadaver procurement dries up or the facility loses its ISO 13485 certification, new clearances stop, the platform cannot expand into additional procedures, and the lock-in stops compounding.
How does this company make money?
The company earns money each time a hospital buys a spinal implant or a set of surgical instruments. It also sells the Excelsius robot itself as a large upfront capital purchase. After that sale, hospitals continue paying for software licenses and maintenance contracts on the robot, creating a recurring stream of income on top of the initial equipment sale.
What makes this company hard to replace?
Surgeons who trained on Excelsius cannot apply that training to a different robot — the certification does not transfer, and they would have to go through a completely separate training process. Hospitals that installed Excelsius have also connected its navigation software to their existing imaging systems, and unwinding that integration is time-consuming and expensive. On top of that, FDA clearances are tied to specific implant-robot pairings, so a hospital cannot simply swap in a competitor's implants and keep using the Excelsius robot legally.
What limits this company?
The Audubon cadaveric lab can only train so many surgeons at a time, and it can only work with as many cadavers as it can procure. That physical ceiling determines how fast clinical data piles up, which in turn determines how many new 510(k) applications can be submitted. The FDA clearance clock cannot run faster than the lab does.
What does this company depend on?
The company cannot run without titanium and cobalt-chromium alloys from specialized metals suppliers, FDA 510(k) clearances for each Excelsius robotic procedure type, ISO 13485 certification for its manufacturing facilities, surgeons willing to complete hands-on training at the Musculoskeletal Education and Research Center cadaveric labs, and hospital capital equipment budgets large enough to purchase Excelsius platform installations.
Who depends on this company?
Spine surgeons rely on the Excelsius platform for robotic navigation during complex fusion procedures — without it, they lose that precision guidance entirely. Orthopedic trauma centers depend on the company for rapid production of custom implants in emergency cases. Teaching hospitals use the Audubon cadaveric labs to train resident surgeons in spine procedures, and that training pipeline would stop if the facility closed.
How does this company scale?
Standard implant shapes can be produced in larger volumes by adding more clean room space and CNC machining centers — that part of the business can grow without reinventing anything. But surgeon training cannot be done online or at a distance; it requires physical lab space and actual cadavers at the Audubon facility. As the company tries to expand into more procedure types, that lab remains the fixed chokepoint.
What external forces can significantly affect this company?
If Medicare lowers its reimbursement rates for spinal fusion procedures, hospitals will perform fewer of them, which directly reduces demand for implants and Excelsius use. Titanium prices can spike when the aerospace industry competes for the same metal, pushing up the cost of every implant. In Europe, the company faces the European Medical Device Regulation, which requires a separate and more demanding body of clinical evidence before products can be sold there.
Where is this company structurally vulnerable?
If cadaver supply to the Audubon facility dried up — because of a change in state anatomical gift laws, a broken supply agreement, or a compliance failure that cost the facility its ISO 13485 certification — no new clinical data could be generated. Without that data, no new 510(k) applications could go forward. The Excelsius platform would be frozen at its current set of approved procedures, surgeon adoption would slow, and the lock-in that keeps hospitals from switching to competitors would stop growing.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign in1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock behaving?
Multi-Year Up-Close-Week Share With Profitability And Book-Value Growth
Three observations describe the present configuration: a high share of the trailing three years' weekly closes were higher than the prior week, the company has reported positive net income in each of the last five annual periods, and the book-value-increase-consistency composite over the trailing 5 years is elevated.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
The reported statements, read against the company's own industry.
4 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Three observations have aligned: most-recent-quarter total cash is in the upper portion of its mapped range against most-recent-quarter total debt, EBITDA-to-total-liabilities is in the upper portion of its mapped range, and FCF-to-total-liabilities is in the upper portion of its mapped range.
Low-Leverage Liquidity Configuration
Three balance-sheet observations co-occur: industry-benchmarked current ratio elevated, industry-benchmarked equity ratio elevated, and total cash at MRQ at least equal to total debt. The configuration describes equity-heavy capital structure with cash covering total debt.
Is this company growing?
Multi-Year Revenue And Profit Growth
Three growth observations align: net income CAGR over the trailing 6 years is positive, revenue CAGR over the trailing 6 years is positive, and a growth-consistency composite reads high. Together they describe a multi-year compound-growth pattern.
Multi-Year Revenue, Profit, And Income Growth
Three multi-year observations co-occur: revenue increased year-over-year in each of the last three fiscal years, gross profit (absolute level) increased year-over-year in each of the last four fiscal years, and net income was positive in each of the last five fiscal years. The configuration describes growth-and-profitability persistence across three different windows.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Supply Chain
Scale
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.